Medtronic's most recent trend suggests a bullish bias. One trading opportunity on Medtronic is a Bull Put Spread using a strike $87.50 short put and a strike $82.50 long put offers a potential 12.61% return on risk over the next 34 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $87.50 by expiration. The full premium credit of $0.56 would be kept by the premium seller. The risk of $4.44 would be incurred if the stock dropped below the $82.50 long put strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Medtronic is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Medtronic is bullish.
The RSI indicator is at 74.8 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Medtronic
Medtronic Launches IN.PACT Admiral in Japan, Boosts APV Arm
Thu, 16 Aug 2018 13:13:01 +0000
Medtronic's (MDT) recent launch of IN.PACT Admiral DCB in Japan is expected to boost the top line.
Treatment with ITB Therapy vs. Oral Medication Shows Quality of Life Improvement, Reduction in Spasticity-Related Pain
Thu, 16 Aug 2018 10:01:01 +0000
Therapy Delivered via the Medtronic SynchroMed TM II Infusion System DUBLIN – August 16, 2018 – Medtronic plc (NYSE:MDT) today announced the online publication of `Effect of intrathecal baclofen on pain …
Medtronic Announces Commercial Launch of the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon in Japan
Wed, 15 Aug 2018 14:01:00 +0000
August 15, 2018 – Medtronic plc (MDT) today announced full commercial launch of the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon (DCB) in Japan. IN.PACT Admiral received approval last year from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the treatment of peripheral artery disease (PAD) in the upper leg – specifically, in the thigh (superficial femoral arteries (SFA)) and behind the knee (popliteal arteries). “In Japan, there is a significant need for new technologies to safely and effectively treat PAD,” said Tony Semedo, president, Medtronic Japan.
GlaxoSmithKline’s Pharmaceuticals Segment in Q2 2018
Tue, 14 Aug 2018 11:31:28 +0000
GlaxoSmithKline’s (GSK) Pharmaceuticals segment includes its HIV, respiratory, immuno-inflammation, and established products. In the second quarter, Pharmaceuticals revenue grew 1% YoY (year-over-year) to ~4.23 billion British pounds at constant exchange rates.
Becton, Dickinson Global Foothold Strong, Recalls Rampant
Mon, 13 Aug 2018 13:28:01 +0000
Becton, Dickinson (BDX) gains from solid global foothold in Q3; foreign exchange headwinds raise concern.
Also on Market Tamer…
Follow Us on Facebook